BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 04, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 10/1 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy 1% $64.19
Needham Mark Monane Price target Buy
Aschoff raised his target to $75 from $66 after including 2H12 sales to his model for for Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). He anticipates pivotal Phase II data for Soliris in the indication this...

Read the full 561 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >